🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma

Recruitingn/aAges 18 Years - anyAllRenJi Hospital
NCT05595408 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

In our study, the ultra-deep sequencing of circulating tumor DNA (ctDNA) and urine tumor DNA (utDNA) were performed to assess whether ctDNA and utDNA can be used as predictive biomarkers for the detection of minimal residual disease (MRD) and early diagnosis of UTUC recurrence, and explored the role of ctDNA and utDNA detection of MRD in the prediction of adjuvant therapy efficacy and prognostic evaluation.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * pathological comfirmed T2-4 or N+ and M0 upper tract urothelial carcinoma * Male or female aged ≥18 years old who are willing to sign the informed consent form * have no distant metastasis * have an ECOG 0 to 2 * upper tract urothelial carcinoma patients received radical nephroureterectomy * have no multiple primary carcinoma * received adjuvant chemotherapy or immunotherapy after surgery within 12 weeks * ≥2 postoperative liquid biopsy assessments (T1 and T2) Exclusion Criteria: * a prior history of bladder or synchronous bladder cancer * Pregnant or lactating women, or patients who are fertile but do not take contraceptive measures; * Severe infection; * Severe heart disease; * Uncontrollable neurological or mental disorders; * Severe diabetes mellitus; * Patients with severe autoimmune diseases. * Neoadjuvant therapy exposure * No bilateral UTUC * Surveillance time \< month * \<2 postoperative MRD surveillance assessments
💊

What it tests

  • Adjuvant chemotherapy
  • adjuvant immunotherapy
📍

Where

1 site
Renji Hospital
Shanghai, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy